Literature DB >> 7703222

Clinical use of clozapine in a major urban setting: one year experience.

E W Chow1, E J Collins, S E Nuttall, A S Bassett.   

Abstract

This paper examines the clinical and demographic data of patients in the Clozapine Distribution System in Metropolitan Toronto in the first year after its inception. One hundred and thirty-seven patients were approved for funding during the year. They tended to be young, chronically and markedly ill patients suffering from schizophrenia, primarily with treatment resistance as the reason for clozapine therapy. Only 55 patients completed at least six months of therapy; 15 patients discontinued clozapine before six months of treatment, mainly because of side-effects and/or patients' noncompliance with bloodwork. Three patients discontinued clozapine because of haematological compromise. Clozapine was efficacious for the majority of patients who took it for at least six months, with improvement in all six clinical dimensions examined in the study. Nevertheless, the number of early discontinuation patients significantly lowered the overall effectiveness of clozapine in actual clinical practice.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7703222      PMCID: PMC1188672     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  16 in total

1.  A retrospective study on the long-term efficacy of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year period.

Authors:  L H Lindström
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 2.  Clozapine. A novel antipsychotic agent.

Authors:  R J Baldessarini; F R Frankenburg
Journal:  N Engl J Med       Date:  1991-03-14       Impact factor: 91.245

3.  Prevalence and severity of akathisia in patients on clozapine.

Authors:  B M Cohen; P E Keck; A Satlin; J O Cole
Journal:  Biol Psychiatry       Date:  1991-06-15       Impact factor: 13.382

4.  Duration of a clozapine trial in neuroleptic-resistant schizophrenia.

Authors:  H Y Meltzer
Journal:  Arch Gen Psychiatry       Date:  1989-07

5.  Clozapine for refractory schizophrenia: an open study of 14 patients treated up to 2 years.

Authors:  J A Mattes
Journal:  J Clin Psychiatry       Date:  1989-10       Impact factor: 4.384

6.  A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report.

Authors:  H Y Meltzer; B Bastani; K Y Kwon; L F Ramirez; S Burnett; J Sharpe
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Predictors of response to clozapine therapy.

Authors:  G Honigfeld; J Patin
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia.

Authors:  J A Lieberman; J Yunis; E Egea; R T Canoso; J M Kane; E J Yunis
Journal:  Arch Gen Psychiatry       Date:  1990-10

9.  Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine.

Authors:  H H Van Tol; J R Bunzow; H C Guan; R K Sunahara; P Seeman; H B Niznik; O Civelli
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

10.  Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine.

Authors:  D Pickar; R R Owen; R E Litman; E Konicki; R Gutierrez; M H Rapaport
Journal:  Arch Gen Psychiatry       Date:  1992-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.